Canadian Respiratory Journal

Research Article

Clinical Features and Risk Factors for Mortality in Hospitalized Older Adults with Pneumonia

Table 2

Comparison of pneumococcal vaccinated and unvaccinated patients.


	Vaccinated	Unvaccinated	value
	n = 38 (%)	n = 55 (%)	value

Laboratory findings at pneumonia onset
Pneumococcal urinary antigen positive	6 (15.8)	18 (32.7)	0.09
Albumin (g/dL), median (IQR)	3.2 (2.9–3.6)	3.0 (2.6–3.6)	0.22

ABG analysis
pH, median (IQR)	7.46 (7.40–7.48)	7.45 (7.39–7.48)	0.49
PaO₂ (mmHg), median (IQR)	64.0 (56.0–80.4)	69.8 (60.4–81.3)	0.39
PaCO₂ (mmHg), median (IQR)	35.9 (31.6–43.8)	36.6 (31.4–45.0)	0.91
A-DROP, median (IQR)	2 (2-3)	2 (1–3)	0.56

Treatment
Anti-pseudomonal antibiotic regimens	12 (31.2)	13 (23.6)	0.40
Steroid therapy	12 (31.2)	16 (29.1)	0.80

Outcome
Days of hospitalization, median (IQR)	12 (10–22)	14 (8–28)	0.62
Death	6 (15.8)	5 (9.1)	0.33

IQR: interquartile range; PaO₂: partial pressure of oxygen; PaCO₂: partial pressure of carbon dioxide; ABG: arterial blood gas. Anti-pseudomonal antibiotic regimens: β-lactams (piperacillin-tazobactam and cefepime), fluoroquinolones (levofloxacin), or carbapenems (meropenem).